<DOC>
	<DOCNO>NCT00001047</DOCNO>
	<brief_summary>To compare safety efficacy two dos clarithromycin combination ethambutol either rifabutin clofazimine treatment disseminate Mycobacterium avium Complex ( MAC ) disease AIDS patient . Recommendations issue AIDS patient disseminate MAC treat least two antimycobacterial agent every regimen include macrolide ( clarithromycin azithromycin ) . However , optimal treatment disseminate MAC remain unknown .</brief_summary>
	<brief_title>Study Four Different Treatment Approaches Patients Who Have Mycobacterium Avium Complex Disease ( MAC ) Plus AIDS</brief_title>
	<detailed_description>Recommendations issue AIDS patient disseminate MAC treat least two antimycobacterial agent every regimen include macrolide ( clarithromycin azithromycin ) . However , optimal treatment disseminate MAC remain unknown . Patients randomize receive clarithromycin one two dos plus ethambutol either rifabutin clofazimine . Patients follow 1 , 2 , 4 month every 4 month thereafter minimum 1.5 year common closing date .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Clofazimine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended patient CD4 count &lt; = 200 cells/mm3 : Antiretroviral therapy . PCP prophylaxis . Allowed patient : Isoniazid preventive therapy . Patients must : HIV infection . Evidence disseminate MAC infection . NOTE : Pregnant woman permit enroll follow counsel clinician regard potential negative side effect study medication . These drug use pregnancy potential benefit outweigh risk . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known hypersensitivity study drug . Other concurrent mycobacterial disease require therapy , i.e. , disseminate nontuberculous mycobacterial infection active tuberculosis . Concurrent Medication : Excluded : Additional medication antimycobacterial activity ( unless patient fail intolerant assign study regimen ) . Drugs potential additive toxicity potential interaction study drug ( e.g. , fluconazole ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ethambutol</keyword>
	<keyword>Clofazimine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Clarithromycin</keyword>
</DOC>